A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors.

Trial Profile

A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs RGT 100 (Primary) ; RGT 100 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Rigontec
  • Most Recent Events

    • 03 May 2017 According to a Rigontec media release, first patient has been dosed in the study.
    • 11 Apr 2017 Planned End Date changed from 1 Sep 2018 to 1 Dec 2019.
    • 11 Apr 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top